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OBJECTIVE—To assess the association between diagnosed diabetes and self-reported cancer
among U.S. adults.
RESEARCH DESIGN AND METHODS—We analyzed data for 397,783 adults who
participated in the 2009 Behavioral Risk Factor Surveillance System and had valid data on di-
abetes and cancer.
RESULTS—After adjustment for potential confounders, diabetic men had higher adjusted
prevalence ratios for cancers of the prostate (1.1 [95% CI 1.0–1.3]), colon (1.3 [1.0–1.7]),
pancreas (4.6 [1.8–11.7]), rectum (2.2 [1.0–4.7]), urinary bladder (1.7 [1.2–2.2]), and kidney
(1.9 [1.2–3.0]) than nondiabetic men (all P , 0.05). Diabetic women had higher adjusted
prevalence ratios for cancers of the breast (1.1 [1.0–1.3]) and endometrium (1.6 [1.2–2.0]),
and leukemia (2.3 [1.3–4.2]) than nondiabetic women (all P , 0.05).
CONCLUSIONS—Our results suggest that diabetic adults have higher prevalences of certain
cancers than nondiabetic adults.
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D iabetes and cancer are two commonchronic diseases that exert seriousadverse effects on public health in
the U.S. Approximately 25.6million adults
(11.3%) aged 20 years or older were es-
timated to have diabetes in 2010 (1). Ap-
proximately 11.7 million Americans were
living with cancer in 2007. Studies have
found that diabetes is associated with an
increased risk for certain types of cancer
(2,3), and diabetes may increase the risk
of all-cause mortality among people with
cancer (4). To compare the prevalence of
cancer between adults without and with
diabetes, we analyzed a large population–
based sample from the Centers for Disease
Control and Prevention 2009 Behavioral
Risk Factor Surveillance System (BRFSS)
in the U.S.
RESEARCH DESIGN AND
METHODS—The BRFSS is a standard-
ized telephone survey that annually as-
sesses key behavioral risk factors and
chronic diseases among adults aged 18
years or older in all U.S. states, District of
Columbia, and territories. The median
cooperation rate among states was 75.0%
in 2009 (5). BRFSS data have consistently
provided valid and reliable estimates
compared with national household sur-
veys (6,7).
Diabetes status was ascertained by
asking participants, “Have you ever been
told by a doctor that you have diabetes?”
Responses were coded as “yes,” “yes, but
female told only during pregnancy,” or
“no.” Gestational diabetes was coded as
“no” diabetes.
Cancer status was ascertained by ask-
ing participants, “Have you ever been told
by a doctor, nurse, or other health pro-
fessional that you have cancer?” Respon-
ses were coded as “yes,” or “no.” For those
who answered “yes” to this question, the
following questions were asked, “With
your most recent diagnoses of cancer,
what type of cancer was it?” The survey
included 10 major cancer sites/tracts and
29 cancer types: breast cancer, male re-
productive tract (prostate cancer, testicu-
lar cancer), head/neck (head and neck
cancer, oral cancer, pharyngeal cancer,
thyroid cancer), gastrointestinal tract (co-
lon cancer, esophageal cancer, liver can-
cer, pancreatic cancer, rectal cancer,
stomach cancer), leukemia/lymphoma
(Hodgkin’s lymphoma, leukemia, non–
Hodgkin’s lymphoma), skin (melanoma,
other skin cancer), lung cancer, urinary
tract (urinary bladder cancer, kidney can-
cer), and other sites (heart cancer, bone
cancer, brain cancer, neuroblastoma,
other).
Demographic characteristics in-
cluded sex, age (year), and race/ethnicity
(non–Hispanic white, non–Hispanic
black, Hispanic, and other). Health-
related risk factors included health insur-
ance coverage (none vs. any type of health
insurance), smoking status (current
smoker, former smoker, and never
smoked), heavy drinking (consuming
more than two drinks per day among
men and more than one drink per day
among women), BMI (kg/m2), and phys-
ical inactivity.
We estimated the crude prevalence
for cancer of all sites and specific types of
cancer according to diabetes status. We
estimated the prevalence ratios and their
95% CIs using log-linear models with a
robust error variance estimator (8). The
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Table 1—Prevalences and prevalence ratios of cancer according to diabetes status among men and women, BRFSS 2009
Cancer site/tract Cancer type
Crude prevalence, % (SE) Prevalence ratio (95% CI)
Diabetes No diabetes P Model 1* Model 2† Model 3‡
Men, N 19,719 131,740
All cancers 15.89 (0.45) 7.49 (0.11) ,0.0001 2.1 (2.0–2.3) 1.1 (1.0–1.1) 1.1 (1.1–1.2)
Breast cancer 0.10 (0.04) 0.02 (0.01) 0.029 5.2 (2.1–12.7) 3.0 (1.2–7.1) 1.5 (0.4–4.8)
Male reproductive 5.35 (0.31) 2.06 (0.06) ,0.0001 2.6 (2.3–3.0) 1.1 (1.0–1.3) 1.1 (1.0–1.3)
Prostate 5.11 (0.31) 1.89 (0.05) ,0.0001 2.7 (2.4–3.1) 1.2 (1.0–1.3) 1.1 (1.0–1.3)
Testicular 0.27 (0.06) 0.18 (0.03) 0.20 1.5 (0.9–2.5) 1.2 (0.7–2.1) 1.1 (0.5–2.2)
Head/neck 0.58 (0.09) 0.27 (0.02) 0.0006 2.2 (1.6–3.1) 1.2 (0.8–1.6) 1.2 (0.8–1.7)
Head and neck 0.11 (0.04) 0.06 (0.01) 0.18 1.9 (0.9–3.8) 1.0 (0.5–2.0) 1.2 (0.6–2.5)
Oral 0.07 (0.03) 0.05 (0.01) 0.43 1.5 (0.6–3.4) 0.9 (0.4–1.8) 0.9 (0.4–2.1)
Pharyngeal 0.14 (0.04) 0.06 (0.01) 0.066 2.2 (1.2–4.2) 1.0 (0.5–1.9) 1.0 (0.5–1.9)
Thyroid 0.26 (0.07) 0.10 (0.01) 0.014 2.7 (1.5–4.8) 1.6 (0.9–2.8) 1.4 (0.8–2.6)
Gastrointestinal 1.90 (0.17) 0.58 (0.03) ,0.0001 3.2 (2.7–4.0) 1.5 (1.2–1.8) 1.4 (1.2–1.8)
Colon 1.37 (0.15) 0.42 (0.02) ,0.0001 3.2 (2.5–4.1) 1.5 (1.1–1.8) 1.3 (1.0–1.7)
Esophageal 0.03 (0.01) 0.03 (0.01) 0.95 1.0 (0.5–2.1) 0.4 (0.2–0.9) 0.6 (0.3–1.4)
Liver 0.12 (0.04) 0.03 (0.01) 0.022 3.7 (1.8–7.6) 1.9 (0.9–4.0) 1.8 (0.9–3.4)
Pancreatic 0.16 (0.07) 0.02 (0.01) 0.034 7.0 (2.8–17.3) 3.4 (1.4–8.3) 4.6 (1.8–11.7)
Rectal 0.14 (0.04) 0.03 (0.01) 0.003 4.7 (2.6–8.8) 2.1 (1.1–4.0) 2.2 (1.0–4.7)
Stomach 0.09 (0.03) 0.04 (0.01) 0.12 2.2 (1.0–4.5) 1.1 (0.5–2.2) 1.0 (0.4–2.5)
Leukemia/lymphoma 0.68 (0.10) 0.44 (0.04) 0.026 1.6 (1.1–2.2) 1.0 (0.7–1.4) 1.1 (0.8–1.6)
Hodgkin’s
lymphoma
0.32 (0.08) 0.14 (0.02) 0.023 2.4 (1.4–4.1) 1.7 (0.9–3.0) 1.8 (0.9–3.4)
Leukemia 0.15 (0.04) 0.13 (0.02) 0.61 1.2 (0.7–2.1) 0.7 (0.4–1.2) 0.8 (0.5–1.6)
Non–Hodgkin’s
lymphoma
0.21 (0.05) 0.17 (0.03) 0.53 1.2 (0.7–2.2) 0.8 (0.5–1.4) 0.8 (0.4–1.4)
Skin 5.57 (0.27) 3.09 (0.06) ,0.0001 1.8 (1.6–2.0) 0.9 (0.8–1.0) 1.0 (0.9–1.1)
Melanoma 2.01 (0.15) 0.99 (0.04) ,0.0001 2.0 (1.7–2.4) 1.0 (0.8–1.2) 1.1 (0.9–1.3)
Other skin 3.71 (0.23) 2.14 (0.05) ,0.0001 1.7 (1.5–2.0) 0.9 (0.8–1.0) 1.0 (0.9–1.1)
Lung 0.38 (0.06) 0.19 (0.02) 0.0036 2.0 (1.3–2.9) 0.9 (0.6–1.3) 0.8 (0.5–1.4)
Urinary 1.35 (0.14) 0.33 (0.02) ,0.0001 4.1 (3.2–5.1) 1.8 (1.4–2.3) 1.7 (1.3–2.2)
Bladder 0.86 (0.11) 0.22 (0.02) ,0.0001 4.0 (3.0–5.3) 1.7 (1.3–2.3) 1.7 (1.2–2.2)
Kidney 0.50 (0.09) 0.12 (0.01) ,0.0001 4.3 (2.9–6.4) 2.2 (1.4–3.3) 1.9 (1.2–3.0)
Other sites 1.53 (0.15) 0.70 (0.04) ,0.0001 2.2 (1.8–2.7) 1.2 (1.0–1.5) 1.2 (1.0–1.6)
Heart Rare§ Rare — — — —
Bone 0.11 (0.04) 0.06 (0.02) 0.28 1.9 (0.7–4.9) 1.6 (0.7–3.9) 1.5 (0.6–3.7)
Brain 0.07 (0.03) 0.04 (0.01) 0.33 1.7 (0.7–3.9) 1.6 (0.7–4.0) 2.2 (0.9–5.6)
Neuroblastoma Rare Rare — — — —
Other 1.36 (0.14) 0.60 (0.03) ,0.0001 2.3 (1.8–2.8) 1.2 (0.9–1.5) 1.2 (1.0–1.5)
Women, N 28,699 217,625
All cancers 17.08 (0.39) 10.37 (0.11) ,0.0001 1.7 (1.6–1.7) 1.1 (1.0–1.1) 1.1 (1.1–1.2)
Breast 5.52 (0.24) 2.87 (0.06) ,0.0001 1.9 (1.8–2.1) 1.1 (1.0–1.2) 1.1 (1.0–1.3)
Reproductive 4.08 (0.25) 2.22 (0.06) ,0.0001 1.8 (1.6–2.1) 1.5 (1.3–1.7) 1.3 (1.2–1.6)
Cervical 1.87 (0.15) 1.36 (0.05) 0.0011 1.4 (1.2–1.6) 1.3 (1.1–1.6) 1.2 (1.0–1.5)
Endometrial 1.45 (0.17) 0.45 (0.02) ,0.0001 3.2 (2.5–4.1) 2.0 (1.6–2.6) 1.6 (1.2–2.0)
Ovarian 0.87 (0.13) 0.44 (0.03) 0.0011 2.0 (1.4–2.7) 1.5 (1.1–2.1) 1.4 (0.9–2.0)
Head/neck 0.67 (0.08) 0.42 (0.02) 0.0023 1.6 (1.2–2.1) 1.1 (0.8–1.4) 1.1 (0.8–1.5)
Head and neck 0.07 (0.02) 0.05 (0.01) 0.38 1.4 (0.7–2.9) 0.8 (0.4–1.7) 1.1 (0.5–2.2)
Oral 0.07 (0.03) 0.03 (0.01) 0.21 2.0 (0.8–4.7) 1.1 (0.4–2.6) 1.0 (0.3–3.0)
Pharyngeal 0.06 (0.02) 0.03 (0.005) 0.18 2.2 (0.9–5.0) 1.3 (0.5–3.1) 1.3 (0.6–3.0)
Thyroid 0.48 (0.07) 0.31 (0.02) 0.019 1.5 (1.1–2.1) 1.1 (0.8–1.5) 1.1 (0.8–1.6)
Gastrointestinal 1.42 (0.12) 0.59 (0.03) ,0.0001 2.4 (2.0–2.9) 1.3 (1.1–1.5) 1.2 (0.9–1.5)
Colon 1.12 (0.10) 0.47 (0.02) ,0.0001 2.4 (2.0–2.9) 1.3 (1.0–1.6) 1.1 (0.9–1.4)
Esophageal Rare 0.02 (0.003) — — — —
Liver 0.10 (0.04) 0.02 (0.01) 0.071 4.7 (1.7–12.7) 3.2 (1.1–9.3) 2.9 (0.9–9.6)
Pancreatic 0.08 (0.03) 0.02 (0.005) 0.032 3.6 (1.6–7.8) 2.0 (0.9–4.4) 2.5 (0.9–6.8)
Rectal 0.08 (0.03) 0.04 (0.01) 0.11 2.2 (1.1–4.7) 1.2 (0.6–2.4) 1.2 (0.5–2.8)
1366 DIABETES CARE, VOLUME 34, JUNE 2011 care.diabetesjournals.org
Diabetes and cancer among U.S. adults
equality in the prevalence estimates was
tested with a two-sample t test. We con-
sidered results with a two-tailed P value
,0.05 or the 95% CI of a prevalence ratio
estimate that did not include 1 to be sta-
tistically significant.
We conducted all analyses using
SUDAAN 9.0 software (Research Triangle
Institute, Research Triangle Park, NC) to
account for the complex sampling design.
RESULTS—The final analytic sample of
397,783 individuals (mean age, 46.8 years;
range, 18–99 years or older; SE = 0.06
years) consisted of 151,459 men (38.1%),
318,070 non–Hispanic whites (80.0%),
31,168 non–Hispanic blacks (7.8%),
26,764 Hispanics (6.7%), and 21,781
other racial/ethnic participants (5.5%).
After adjustment for age and all other
potential confounders, men with diabetes
had significantly higher prevalences of
cancer of all sites and cancers of the
prostate, colon, pancreas, rectum, urinary
bladder, and kidney than men without
diabetes (Table 1). Women with diabetes
had significantly higher prevalences
of cancer of all sites and cancers of the
breast and endometrium as well as leuke-
mia than women without diabetes (all
P , 0.05). Diabetic men had a higher
prevalence of liver cancer, whereas dia-
betic women had a higher prevalence of
liver cancer and pancreatic cancer than
their nondiabetic counterparts, albeit no
statistical significance was detected (P =
0.07–0.13).
CONCLUSIONS—Our prevalence ra-
tio estimates for the cancer of all sites
amongmen andwomen were comparable
to relative risk estimates in studies on
cancer incidence (3,9). Our results sup-
port an association between diabetes and
cancer. Previous findings have shown that
diabetes is linked to an increased risk of
cancers of the pancreas, liver, kidney, co-
lorectal, urinary bladder, endometrium,
breast, and non–Hodgkin’s lymphoma
(3). The possible biologic mechanisms
that link diabetes and cancer include hy-
perinsulinemia, hyperglycemia, and/or
chronic inflammation (2).
These findings have significant public
health implications because the strong
associations of diabetes with certain can-
cer types may inform public health deci-
sions and policies regarding the priorities
of cancer screening and clinical manage-
ment. Regular screening is an important
tool to detect certain types of cancer early
in their onset, particularly those with high
prevalence among adults with diabetes.
As shown in a previous study (10), U.S.
women with diagnosed diabetes had low
rates of screening for cancers of the breast,
cervix, colon and rectum compared with
recommended levels. Moreover, diabetic
women were less likely to be screened for
cervical cancer compared with nondiabetic
women. Therefore, enhanced efforts may
be needed to promote cancer screening,
particularly for the cancers highly related
to diabetes, as evidenced in our study.
Our results were subject to several
limitations. First, although there is a sub-
stantial agreement in determinations of
diabetes status by self-reports and those
based on actual diagnoses (11), misclassi-
fication bias of the diabetes status of par-
ticipants with undiagnosed diabetes
could have resulted in the underestima-
tion of our results. Second, the BRFSS
survey excludes adults who have been in-
stitutionalized or hospitalized and those
with only mobile telephones, which may
have led us to underestimate the true
prevalence of cancer.
In conclusion, our results suggest that
adults with diabetes had a higher preva-
lence of cancer than those without di-
abetes. These findings highlight a need
for increased attention to and efforts in
Table 1—Continued
Cancer site/tract Cancer type
Crude prevalence, % (SE) Prevalence ratio (95% CI)
Diabetes No diabetes P Model 1* Model 2† Model 3‡
Stomach 0.04 (0.01) 0.03 (0.01) 0.40 1.4 (0.7–3.0) 0.8 (0.4–1.7) 0.9 (0.4–2.0)
Leukemia/lymphoma 0.63 (0.09) 0.36 (0.02) 0.0019 1.8 (1.3–2.4) 1.1 (0.9–1.5) 1.2 (0.8–1.6)
Hodgkin’s
lymphoma
0.17 (0.05) 0.12 (0.01) 0.34 1.4 (0.8–2.5) 1.0 (0.5–1.8) 1.0 (0.5–1.8)
Leukemia 0.30 (0.06) 0.10 (0.01) 0.0015 3.1 (1.9–4.9) 2.0 (1.3–3.4) 2.3 (1.3–4.2)
Non–Hodgkin’s
lymphoma
0.16 (0.03) 0.14 (0.01) 0.51 1.2 (0.8–1.8) 0.7 (0.5–1.1) 0.7 (0.4–1.1)
Skin 4.35 (0.20) 3.25 (0.06) ,0.0001 1.3 (1.2–1.5) 0.8 (0.7–0.9) 1.0 (0.9–1.2)
Melanoma 1.35 (0.12) 0.90 (0.03) 0.0004 1.5 (1.2–1.8) 0.9 (0.8–1.1) 1.2 (1.0–1.5)
Other skin 3.08 (0.16) 2.39 (0.05) 0.0001 1.3 (1.2–1.4) 0.7 (0.7–0.8) 1.0 (0.9–1.1)
Lung 0.37 (0.05) 0.24 (0.02) 0.0314 1.5 (1.1–2.2) 0.8 (0.6–1.2) 0.7 (0.4–1.1)
Urinary 0.43 (0.06) 0.19 (0.01) 0.0002 2.3 (1.7–3.2) 1.2 (0.9–1.7) 1.2 (0.8–1.6)
Bladder 0.19 (0.04) 0.10 (0.01) 0.009 2.0 (1.3–3.0) 1.0 (0.7–1.5) 0.9 (0.6–1.3)
Kidney 0.24 (0.05) 0.09 (0.01) 0.0071 2.6 (1.6–4.4) 1.6 (1.0–2.6) 1.6 (0.9–2.7)
Other sites 1.60 (0.15) 0.84 (0.04) ,0.0001 1.9 (1.6–2.3) 1.3 (1.0–1.5) 1.2 (0.9–1.4)
Heart Rare Rare — — — —
Bone 0.05 (0.02) 0.05 (0.01) 0.94 1.0 (0.5–2.1) 0.9 (0.4–1.7) 0.9 (0.4–2.0)
Brain 0.04 (0.02) 0.06 (0.01) 0.54 0.7 (0.3–2.1) 0.8 (0.3–2.1) 0.7 (0.2–2.8)
Neuroblastoma Rare Rare — — — —
Other 1.50 (0.14) 0.73 (0.03) ,0.0001 2.1 (1.7–2.5) 1.3 (1.1–1.6) 1.2 (1.0–1.5)
*Model 1: unadjusted. †Model 2: adjusted for age (years, continuous) only. ‡Model 3: adjusted for age (years, continuous), race/ethnicity (non–Hispanic white, non–
Hispanic black, Hispanic, other), health insurance coverage (any vs. none), smoking status (current smoker, former smoker, never smoked), heavy drinking (yes,
consuming more than two drinks per day among men andmore than one drink per day among women vs. no), BMI (kg/m2, continuous), and physical inactivity (yes
vs. no). §Rare: prevalence estimate is between 0 and 0.01%. Statistical tests are not provided due to insufficient data.
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preventing and screening for certain can-
cers to reduce the disease burden and
improve the quality of life among adults
with diabetes in the general population.
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